Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer
This study is to assess the biodistribution and kinetics of a novel T-cell imaging agent in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy. This study is assessing the change in kinetics that occurs in this patient population to better understand the distribution of this compound in patient disease circumstances.
Checked against the public recordLast updated May 13, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Basic Science
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- University of Tennessee
- Interventions being studied
- Drug: 18F-AraG
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * This study is open to all adult subjects with histological confirmation of NSCLC enrolled in the parent protocol. * Age 21 years of age or greater * ECOG performance status of 0, 1, 2 or 3 at the time of enrollment. * Patient with life expectancy ≥ 24 weeks from the time of screening to the study * Ability to give informed consent Exclusion Criteria: * Patients with severe claustrophobia (patients with milder forms of claustrophobia that can be successfully allayed with oral anxiolytic therapy are allowed). * Severe impaired renal function with estimated glomerular filtration rate \<30 mL/min/1.73 m2 and/or on dialysis. * Pregnancy * Breast Feeding an infant * Unable to tolerate the expected radiation therapy prescription
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Tennessee Medical CenterKnoxville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 13, 2022. Always confirm current availability with the study team.